Vanguard Fiduciary Trust
RNTX

Vanguard Fiduciary Trust’s Rein Therapeutics RNTX Stock Holding History

Vanguard Fiduciary Trust’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$398K Buy
382,515
+228,003
+148% +$276K ﹤0.01% 3353
2026
Q1 		$201K Buy
+154,512
New +$192K ﹤0.01% 3521

Other funds holding RNTX

VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

Vanguard Fiduciary Trust's RNTX Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Rein Therapeutics (RNTX) stake by 148% in Q2 2026, buying an estimated $276K and bringing the position to 382,515 shares worth $398K. The position accounts for ﹤0.01% of the portfolio, ranked #3353.

Vanguard Fiduciary Trust first reported a position in RNTX in Q1 2026 and has held it in 2 quarters since. 60 funds tracked by Wall St. Rank hold RNTX as of Q2 2026.

  • Vanguard Fiduciary Trust held 382,515 shares of Rein Therapeutics worth $398K as of Q2 2026.
  • Vanguard Fiduciary Trust bought 228,003 Rein Therapeutics shares in Q2 2026, an estimated $276K.
  • Rein Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3353 holding.
  • Vanguard Fiduciary Trust first reported a position in Rein Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 60 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.